HIV-1 subtype and drug resistance in HIV/AIDS patients who failed in antiretroviral therapy in Jinhua City
WU Bin1, FANG Qionglou1, ZHU Ke2
1. Department of Laboratory Testing, Jinhua Center for Disease Control and Prevention, Jinhua, Zhejiang 321002, China; 2. Jinhua Center for Disease Control and Prevention, Jinhua, Zhejiang 321002, China
Abstract：Objective To investigate HIV-1 subtypes and drug resistance in HIV/AIDS patients who failed in antiretroviral therapy in Jinhua City, Zhejiang Province, so as to provide the basis for improving antiretroviral therapy strategy. Methods Totally 128 plasma samples of HIV/AIDS patients who failed in antiretroviral therapy (treatment for more than 6 months and viral load ≥1 000 copies/mL) from January 1 to November 30, 2023 were collected. After nucleic acid extraction and amplification, the sequences of HIV-1 pol genes were determined using first generation sequencing method, then submitted to HIV resistance database of Stanford University in the United States, and the subtypes, drug resistance mutations and drug resistance status of HIV-1 were analyzed. Results A total of 118 sequences of HIV/AIDS patients were obtained, including 94 males and 24 females (male to female ratio, 3.9︰1). There were 53 cases aged between 40 to 59 years, accounting for 44.92%. The main infection routes was heterosexual contact, with 92 cases accounting for 77.97%. The main HIV-1 gene subtypes were CRF07_BC and CRF01_AE, with 45 and 39 cases accounting for 38.14% and 33.05%, respectively. There were 75 cases found to have drug-resistant site mutations, with a mutation rate of 63.56%. The most common mutation sites were M184 and K103, with mutation rates of 29.66% and 28.81%, respectively. There were 58 cases with resistance to more than one drug, with a rate of 49.15%. The rates of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI), nucleotide reverse transcriptase inhibitors (NRTI) and protease inhibitors (PI) were 50.00%, 33.90% and 4.24%, respectively. Conclusion The HIV-1 gene subtypes of HIV/AIDS patients who failed in antiretroviral therapy in Jinhua City are mainly CRF07_BC and CRF01_AE, which are mainly resistant to NNRTI and NRTI.
[1] 严海波,于伟,吴燕芬,等.柯桥区未接受抗病毒治疗HIV/AIDS病例调查[J].预防医学,2021,33(9):910-912. [2] LUO X L,MO L D,SU G S,et al.Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy[J].J Pharmacol Sci,2019,139(4):275-279. [3] CHIMUKANGARA B,LESSELLS R J,RHEE S Y,et al.Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naive adults in South Africa,2000-2016:a pooled sequence analysis[J].EClinicalMedicine,2019,9:26-34. [4] 阮尉月清,刘家法,张米,等.云南省男男性行为人群HIV/AIDS病例抗病毒治疗失败基因型耐药分析[J].预防医学,2020,32(10):987-991. [5] 郭琪,王慧,臧希卉,等.吉林省抗病毒治疗失败HIV/AIDS患者HIV-1毒株基因型耐药特征[J].中国国境卫生检疫杂志,2023,46(6):583-588. [6] 赵宏儒,路新利,赵翠英,等.河北省未治疗患者体内HIV毒株耐药基因检测研究[J].河北医药,2010,32(12):1531-1533. [7] 雷亚克,戴莹,周康平,等.2017—2018年湖北省HIV-1抗病毒治疗失败患者耐药检测结果分析[J].公共卫生与预防医学,2020,31(3):73-75. [8] 陈素庭,洪航,许国章.抗病毒治疗的HIV/AIDS病例高血糖的影响因素分析[J].预防医学,2022,34(11):1110-1115,1120. [9] ZHANG J F,GUO Z H,YANG J Z,et al.Genetic diversity of HIV-1 and transmitted drug resistance among newly diagnosed individuals with HIV infection in Hangzhou,China[J].J Med Virol,2015,87(10):1668-1676. [10] 钟平. HIV分子流行病学研究和实践进展[J].新发传染病电子杂志,2019,4(3):137-144. [11] 汪宁,钟平.中国HIV分子流行病学30年[J].中华流行病学杂志,2015,369(6):541-546. [12] 缪礼锋,沈月兰,苏斌,等.安徽省485例抗病毒治疗失败艾滋病患者耐药基因型分析[J].中国卫生检验杂志,2019,29(19):2339-2343,2346. [13] 林俊潇,王红珠,李聪聪,等.治疗失败的HIV感染者HIV-1亚型及耐药突变位点分析[J].上海预防医学,2023,35(3):224-227. [14] 赵砚,吕娅妮,康续,等.239例治疗失败的HIV感染者HIV-1亚型及耐药分析[J].中国艾滋病性病,2020,26(10):1045-1048. [15] 王颖,杨金翰,杨虹,等.内蒙古抗病毒治疗失败患者HIV-1毒株耐药分析[J].中国卫生检验杂志,2021,31(19):2352-2356. [16] 吴亚松,马烨.中国艾滋病病毒耐药现状[J].新发传染病电子杂志,2019,4(3):181-184. [17] 陈剑双,殷玥琪,成浩,等.2014—2016年无锡市HIV/AIDS病毒亚型及耐药变化分析[J].南京医科大学学报(自然科学版),2021,41(4):612-616,627.
